Lanean...
Combination of clinically utilized kappa opioid receptor agonist nalfurafine with low-dose naltrexone reduces excessive alcohol drinking in male and female mice
BACKGROUND: Nalfurafine is the first clinically approved kappa-opioid receptor (KOP-r) agonist as an anti-pruritus drug with few side effects in humans (e.g., sedation, depression and dysphoria). No study, however, has been done using nalfurafine on alcohol drinking in rodents or humans. METHODS: We...
Gorde:
| Argitaratua izan da: | Alcohol Clin Exp Res |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6551307/ https://ncbi.nlm.nih.gov/pubmed/30908671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/acer.14033 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|